Trial Profile
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 11 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Sep 2024.
- 04 Jan 2023 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 04 Jan 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.